ArticleAnnals of African medicine2025
Combination of Tapentadol Nasal Spray and Radiotherapy for Managing Moderate-to-Severe Pain from Lytic Bone Metastasis.
Article in Annals of African medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTapentadol is known for its opioid-sparing effect, reducing adverse effects associated with opioids, particularly gastrointestinal issues. However, limitations in the oral formulation warrant exploration of alternatives like tapentadol nasal spray for enhanced efficacy and patient experience. AIMS AND
objectivesThis study aimed to assess the safety of tapentadol nasal spray (45mg/dose, administered four times daily) along with radiotherapy in patients with lytic bony metastasis moderate to severe pain. MATERIALS AND
methods65 patients with lytic bony metastasis from solid tumours in 2023 were given local radiotherapy and tapentadol nasal spray (45mg/dose, administered four times daily).
resultsTapentadol nasal spray combined with radiotherapy demonstrated significant pain reduction. Sleep scores were significantly better with tapentadol nasal spray. The nasal route provided enhanced comfort, convenience, safety, and efficacy, offering rapid pain relief.
conclusionTapentadol nasal spray presents a favourable option for bone metastasis pain management along with radiotherapy, offering improved pain reduction, better sleep outcomes, and enhanced patient comfort. The nasal delivery method proves efficient and patient-friendly, marking a significant advancement in achieving early and sustained pain relief.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.